Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 15/20 | 0.51 |
| ▸ | AKT1 | P31749 | 1/20 | 0.51 |
| ▸ | AKT2 | P31751 | 1/20 | 0.51 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 18/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 15/20 | 0.48 |
| ▸ | PRKDC | P78527 | 1/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.44 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.44 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3201554 | 0.87 | PIK3CB (0.64) | PIK3CAPIK3CBPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL25416996 | 0.86 | PIK3CB (0.46) | PIK3CAPIK3CBPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL25358740 | 0.82 | PIK3CA (0.60) | PIK3CAAKT1AKT2AKT3PIK3CB | |
| SCHEMBL25360345 | 0.81 | PIK3CA (0.56) | PIK3CAAKT1AKT2AKT3PIK3CB | |
| SCHEMBL30858246 | 0.81 | PIK3CB (0.47) | PIK3CAAKT1AKT2AKT3PIK3CB | |
| SCHEMBL27121826 | 0.81 | PIK3CA (0.61) | PIK3CAAKT1AKT2AKT3PIK3CB | |
| SCHEMBL27153046 | 0.81 | CHRM3 (0.43) | PIK3CAAKT1AKT2AKT3PIK3CB | |
| SCHEMBL32688089 | 0.81 | PIK3CA (0.48) | PIK3CAAKT1AKT2AKT3PIK3CB | |
| SCHEMBL25358982 | 0.80 | PIK3CA (0.60) | PIK3CAAKT1AKT2AKT3PIK3CB | |
| SCHEMBL25364344 | 0.80 | PIK3CA (0.63) | PIK3CAAKT1AKT2AKT3PIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078120-A1 | SUBSTITUTED PYRIDOPYRIMIDINONES | Mirati Therapeutics, Inc. (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4577544-A1 | SUBSTITUTED PYRIDOPYRIMIDINONES | Mirati Therapeutics, Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| US-20250084048-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-03-13 | — | — | US | disclosed |
| EP-4412606-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2024-08-14 | — | — | EP | disclosed |
| CN-118251217-A | PI3K alpha inhibitors and methods of use thereof | 传达治疗有限公司 | 2024-06-25 | — | — | CN | disclosed |
| WO-2024044769-A1 | SUBSTITUTED PYRIDOPYRIMIDINONES | Mirati Therapeutics, Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044769-A1 | SUBSTITUTED PYRIDOPYRIMIDINONES | Mirati Therapeutics, Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2023159155-A1 | INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) AND USES THEREOF | PIVALENT THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023060262-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078120-A1 | SUBSTITUTED PYRIDOPYRIMIDINONES | CBR1, CBR3, CNR1 | PIK3CA 2749/4885AKT1 2105/4885AKT2 2550/4885 |
| US-20250084048-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | PIK3CA, PIK3CB, PIK3CD | PIK3CA 1/4885AKT1 18/4885AKT2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.